Cancer biomarker AKR1B10 and carbonyl metabolism

Chemico-Biological Interactions

Volumn 178, Issue 1-3, 2009, Pages 134-137

  Balendiran, Ganesaratnam K ^a   Martin, Hans Joerg ^b   El Hawari, Yasser ^b   Maser, Edmund ^b  

^a YOUNGSTOWN STATE UNIVERSITY   (United States)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

AKR1B10; Aldo keto reductase; Cancer; Chemotherapy; Inhibitor

Indexed keywords

ALDEHYDE REDUCTASE; ALDO KETO REDUCTASE 1B10 PROTEIN; CARBONYL DERIVATIVE; CIPROFIBRATE; CYSTEINE; DAUNORUBICIN; DOXORUBICINOL; ETHYL 1 BENZYL 3 HYDROXY 2(5H) OXOPYRROLE 4 CARBOXYLIC ACID; FENOFIBRATE; FENOFIBRIC ACID; GEMFIBROZIL; GLYCERALDEHYDE; PIRINIXIC ACID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SERINE; SORBINIL; UNCLASSIFIED DRUG; ZOPOLRESTAT;

ARTICLE; CARBON METABOLISM; CATALYSIS; CONCENTRATION RESPONSE; ENZYME SPECIFICITY; GENE MUTATION; GENETIC POLYMORPHISM; IC 50; INHIBITION KINETICS; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ALDEHYDE REDUCTASE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME INHIBITORS; HUMANS; KINETICS; POLYMORPHISM, GENETIC; PROCETOFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 59049089879     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2008.10.044     Document Type: Article

References (36)

1. Jez J.M., Flynn T.G., and Penning T.M. A new nomenclature for the aldo-keto reductase superfamily. Biochem. Pharmacol. 54 6 (1997) 639-647
2. Cao D., Fan S.T., and Chung S.S. Identification and characterization of a novel human aldose reductase-like gene. J. Biol. Chem. 273 19 (1998) 11429-11435
3. Hyndman D.J., and Flynn T.G. Sequence and expression levels in human tissues of a new member of the aldo-keto reductase family. Biochim. Biophys. Acta. 1399 2-3 (1998) 198-202
4. Scuric Z., Stain S.C., Anderson W.F., and Hwang J.J. New member of aldose reductase family proteins overexpressed in human hepatocellular carcinoma. Hepatology 27 4 (1998) 943-950
5. Fukumoto S., Yamauchi N., Moriguchi H., Hippo Y., Watanabe A., Shibahara J., Taniguchi H., Ishikawa S., Ito H., Yamamoto S., Iwanari H., Hironaka M., Ishikawa Y., Niki T., Sohara Y., Kodama T., Nishimura M., Fukayama M., Dosaka-Akita H., and Aburatani H. Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas. Clin. Cancer Res. 11 5 (2005) 1776-1785
6. Weiss R.B. The anthracyclines: will we ever find a better doxorubicin?. Semin. Oncol. 19 (1992) 670-686
7. W.R. Vogler, E. Velez-Garcia, R.S. Weiner, M.A. Flaum, A.A. Bartolucci, G.A. Omura, M.C. Gerber, P.L. Banks, A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southestern Cancer Study Group study, J Clin Oncol 10 (1992) 1103-1111.
8. Hortobagyi G.N. Anthracyclines in the treatment of cancer. An overview. Drugs 54 Suppl 4 (1997) 1-7
9. Minotti G., Cavaliere A.F., Mordente A., Rossi M., Schiavello R., Zamparelli R., and Possati G. Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity. J. Clin. Invest. 95 4 (1995) 1595-1605
10. Martin H.J., Breyer-Pfaff U., Wsol V., Venz S., Block S., and Maser E. Purification and characterization of akr1b10 from human liver: role in carbonyl reduction of xenobiotics. Drug Metab. Dispos. 34 3 (2006) 464-470
11. Schott B., and Robert J. Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture. Biochem. Pharmacol. 38 22 (1989) 4069-4074
12. Tanaka M., Bateman R., Rauh D., Vaisberg E., Ramachandani S., Zhang C., Hansen K.C., Burlingame A.L., Trautman J.K., Shokat K.M., and Adams C.L. An unbiased cell morphology-based screen for new, biologically active small molecules. PLoS Biol. 3 5 (2005) e128
13. Balendiran G.K., and Rajkumar B. Fibrates inhibit aldose reductase activity in the forward and reverse reactions. Biochem. Pharmacol. 70 11 (2005) 1653-1663
14. Klemin S., Calvo R.Y., Bond S., Dingess H., Rajkumar B., Perez R., Chow L., and Balendiran G.K. WY 14,643 inhibits human aldose reductase activity. J. Enzyme Inhib. Med. Chem. 21 5 (2006) 569-573
15. Balendiran G.K., Verma M., and Perry E. Chemistory of fibrates. Curr. Chem. Biol. 1 3 (2007) 311-316
16. Parry G.J. Management of diabetic neuropathy. Am. J. Med. 107 2B (1999) 27S-33S
17. Pfeifer M.A., Schumer M.P., and Gelber D.A. Aldose reductase inhibitors: the end of an era or the need for different trial designs?. Diabetes 46 Suppl 2 (1997) S82-S89
18. Sato S., and Kador P.F. Inhibition of aldehyde reductase by aldose reductase inhibitors. Biochem. Pharmacol. 40 5 (1990) 1033-1042
19. Vander Jagt D.L., Torres J.E., Hunsaker L.A., Deck L.M., and Royer R.E. Physiological substrates of human aldose and aldehyde reductases. Adv. Exp. Med. Biol. 414 (1996) 491-497
20. Petrash J.M., Harter T.M., Devine C.S., Olins P.O., Bhatnagar A., Liu S., and Srivastava S.K. Involvement of cysteine residues in catalysis and inhibition of human aldose reductase. Site-directed mutagenesis of Cys-80, -298, and -303. J. Biol. Chem. 267 34 (1992) 24833-24840
21. Bohren K.M., and Gabbay K.H. Cys298 is responsible for reversible thiol-induced variation in aldose reductase activity. Adv. Exp. Med. Biol. 328 (1993) 267-277
22. Verma M., Martin H.-J., Haq W., O'Connor T.R., Maser E., and Balendiran G.K. Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers. Euro. J. Pharmacol. 584 (2008) 213-221
23. Rath N.P., Haq W., and Balendiran G.K. Fenofibric acid. Acta Crystallogr. C 61 Pt 2 (2005) o81-o84
24. Teramoto R., Minagawa H., Honda M., Miyazaki K., Tabuse Y., Kamijo K., Ueda T., and Kaneko S. Protein expression profile characteristic to hepatocellular carcinoma revealed by 2D-DIGE with supervised learning. Biochim. Biophys. Acta 1784 5 (2008) 764-772
25. Adkins J.C., Peters D.H., Faulds D., and Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection. Drugs 53 6 (1997) 1054-1080
26. El-Serag H.B., and Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. 340 10 (1999) 745-750
27. Taylor-Robinson S.D., Foster G.R., Arora S., Hargreaves S., and Thomas H.C. Increase in primary liver cancer in the UK, 1979-94. Lancet 350 9085 (1997) 1142-1143
28. Yan R., Zu X., Ma J., Liu Z., Adeyanju M., and Cao D. Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention. Int. J. Cancer 121 10 (2007) 2301-2306
29. Yoshitake H., Takahashi M., Ishikawa H., Nojima M., Iwanari H., Watanabe A., Aburatani H., Yoshida K., Ishi K., Takamori K., Ogawa H., Hamakubo T., Kodama T., and Araki Y. Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer. Int. J. Gynecol. Cancer 17 6 (2007) 1300-1306
30. Kaiserova K., Srivastava S., Hoetker J.D., Awe S.O., Tang X.L., Cai J., and Bhatnagar A. Redox activation of aldose reductase in the ischemic heart. J. Biol. Chem. 281 22 (2006) 15110-15120
31. Downey J.M. Free radicals and their involvement during long-term myocardial ischemia and reperfusion. Annu. Rev. Physiol. 52 (1990) 487-504
32. Kloner R.A., and Jennings R.B. Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 2. Circulation 104 25 (2001) 3158-3167
33. Kaiserova K., Tang X.L., Srivastava S., and Bhatnagar A. Role of nitric oxide in regulating aldose reductase activation in the ischemic heart. J. Biol. Chem. 283 14 (2008) 9101-9112
34. Wouters K.A., Kremer L.C., Miller T.L., Herman E.H., and Lipshultz S.E. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br. J. Haematol. 131 5 (2005) 561-578
35. Minotti G., Menna P., Salvatorelli E., Cairo G., and Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56 2 (2004) 185-229
36. Plebuch M., Soldan M., Hungerer C., Koch L., and Maser E. Increased resistance of tumor cells to daunorubicin after transfection of cDNAs coding for anthracycline inactivating enzymes. Cancer Lett. 255 1 (2007) 49-56